Kinase News and Research

RSS

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy.

23 Feb 2016

FDA-approved VENTANA anti-ALK CDx more accurate than commonly used IHC assay for patient selection

The U.S. Food and Drug Administration approved VENTANA anti-ALK(D5F3)CDx performed more accurately than another commonly used immunohistochemistry (IHC) assay, based on the use of the 5A4 clone, for the selection of patients eligible to receive ALK tyrosine kinase inhibitor (TKI) treatment.

23 Feb 2016

Researchers analyze how Topo II enzyme may affect stability of genomes

While researchers are now familiar with how cancer begins—cells mutate and then multiply wildly out of control—it is still uncertain exactly how that mutation starts in the molecules of the cells.

22 Feb 2016

Study looks at factors that affect physical recovery after participation in ultramarathon

Ultramarathon runners can expect an approximate five-to-seven-day subjective recovery post race, according to research presented this week at the Association of Academic Physiatrists Annual Meeting in Sacramento, Calif. The study also looked at factors that affect physical recovery and a runner's ability to return to full running speed after participation in an ultramarathon.

19 Feb 2016

Vascular Occlusion Risk Reviewed For CML New-Generation TKIs

A meta-analysis highlights the significantly increased risk of vascular occlusive events in patients with chronic myeloid leukaemia using some new-generation BCR-ABL tyrosine kinase inhibitors compared with use of imatinib.

17 Feb 2016

Mtss1 'tumour suppressor' for CML

The metastasis suppressor 1 protein acts a tumour suppressor in chronic myeloid leukaemia stem cells, reveals research published in Leukemia.

17 Feb 2016

CTI BioPharma announces Q4 and FY 2015 earnings

CTI BioPharma Corp. today reported financial results for the fourth quarter and full year ended December 31, 2015.

17 Feb 2016

UAB research reveals heterogonous population of leukemia stem cells

University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today — an inability to get patients off treatment.

16 Feb 2016

Fasudil improves memory in rats, promotes degradation of toxic tau in the eyes of fruit flies

Could a kinase inhibitor some doctors prescribe to keep blood flowing after brain surgery be used to treat neurodegeneration? New research suggests it might be worth exploring the question.

10 Feb 2016

LouLou Foundation, Penn Med set up Program of Excellence to develop treatments for children with CDKL5

The London-based LouLou Foundation and the Orphan Disease Center of the Perelman School of Medicine at the University of Pennsylvania have established a Program of Excellence to develop effective treatments for children with CDKL5, a rare X-chromosome-linked genetic disorder that causes severe neuro-developmental impairment and early-onset, difficult-to-control seizures.

8 Feb 2016

New personalized DNA-based digital assay has potential to dramatically impact CML management

The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor (TKI) treatment. Use of a TKI regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in "molecular remission," however, uncertainties remain regarding whether they will relapse or if treatment should be discontinued.

8 Feb 2016

AstraZeneca’s TAGRISSO (osimertinib) approved in EU for metastatic EGFR T790M mutation-positive NSCLC

AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

4 Feb 2016

Discovery could lead to new leukaemia therapies

Human blood cells have olfactory receptors that respond to Sandalore. This could provide a starting point for new leukaemia therapies, as researchers from Bochum report in in the journal "Cell Death Discovery".

3 Feb 2016

Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.

1 Feb 2016

MGH study may lead to first nonsurgical treatment for seborrheic keratoses

An investigation into the molecular mechanisms responsible for the most common type of benign skin lesion may lead to the first nonsurgical treatment for the growths called seborrheic keratoses (SKs), which in addition to being cosmetically unattractive are often worrisome to patients.

30 Jan 2016

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.

30 Jan 2016

Mutation or amplification of HER2 gene may lead to lung cancer

A joint study by University of Colorado Cancer Center and Memorial Sloan Kettering Cancer Center published in the Journal of Thoracic Oncology shows two distinct causes of HER2 activation in lung cancer: mutation of the gene and amplification of the gene.

29 Jan 2016

Simple blood test could help predict emergence of pre-eclampsia in pregnant women

Pre-eclampsia is a serious illness associated with pregnancy, which develops after twenty weeks and is associated with defective ingrowing of the placenta within the mother. The dangerous illness is both the second most frequent cause of death in pregnant women, and the reason for severe complications for mother and child, especially during premature births.

25 Jan 2016

Positive bosutinib response for elderly blast phase CML patient

A case study suggests that the third-generation tyrosine kinase inhibitor bosutinib may be considered as induction therapy for blast phase chronic myeloid leukaemia in older patients.

22 Jan 2016

Cardiovascular considerations crucial for CML TKI patients

A review of BCR–ABL1 tyrosine kinase inhibitors highlights the need to consider cardiovascular adverse event risk profiles when prescribing for patients with chronic myeloid leukaemia.

22 Jan 2016

Kinase News and Research

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

FDA-approved VENTANA anti-ALK CDx more accurate than commonly used IHC assay for patient selection

Researchers analyze how Topo II enzyme may affect stability of genomes

Study looks at factors that affect physical recovery after participation in ultramarathon

Vascular Occlusion Risk Reviewed For CML New-Generation TKIs

Mtss1 'tumour suppressor' for CML

CTI BioPharma announces Q4 and FY 2015 earnings

UAB research reveals heterogonous population of leukemia stem cells

Fasudil improves memory in rats, promotes degradation of toxic tau in the eyes of fruit flies

LouLou Foundation, Penn Med set up Program of Excellence to develop treatments for children with CDKL5

New personalized DNA-based digital assay has potential to dramatically impact CML management

AstraZeneca’s TAGRISSO (osimertinib) approved in EU for metastatic EGFR T790M mutation-positive NSCLC

Discovery could lead to new leukaemia therapies

Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

MGH study may lead to first nonsurgical treatment for seborrheic keratoses

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

Mutation or amplification of HER2 gene may lead to lung cancer

Simple blood test could help predict emergence of pre-eclampsia in pregnant women

Positive bosutinib response for elderly blast phase CML patient

Cardiovascular considerations crucial for CML TKI patients

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News